Results 51 to 60 of about 56,538 (251)

Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis [PDF]

, 2004
BACKGROUND: This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal pathology as measured by plasma surrogate markers.
Brassat, D., Clanet, M., Giovannoni, G., Keir, G., Mas, P., Petzold, A., Rejdak, K., Thompson, E.J.   +7 more
core   +1 more source

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology

Trials, 2009
Background Statins have anti-inflammatory and immunomodulatory properties in addition to their lipid-lowering effects. Currently, the effects of statins on multiple sclerosis are still controversial.
Mattle Heinrich P, Kamm Christian P
doaj   +1 more source

Inflammatory Activity on Natalizumab Predicts Short-term but not Long-term Disability in Multiple Sclerosis [PDF]

, 2017
BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesions and relapses during the first year of treatment predict a poor prognosis.
Dahdaleh, S, Gafson, AR, Jones, B, Malik, O, Nicholas, R, Raffel, J   +5 more
core   +1 more source

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

Comparison some of the syntactic skills in Relapsing Remitting Multiple sclerosis and normal adults resident in Esfahan Province

مجله پژوهش در علوم توانبخشی, 2013
Introduction: Multiple sclerosis is a progressive disease of the central nervous system that deteriorates myelin sheath and produce plaques in white matters of the brain and spinal cord.
Sedigheh Jamalpour, Nahid Baharlooie, Fereshteh Ashtari, Fereshteh Shamsian, Morteza Sedehi   +4 more
doaj   +1 more source

Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies [PDF]

, 2015
Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is the most prevalent disabling neurological condition among young adults, with onset typically between 20 and 40 years of age. Infiltrating immune cells and microglia
Kay, Kathleen Alexandra
core   +1 more source

Air Pollution and the Risk and Progression of Multiple Sclerosis: A Systematic Review and Meta‐Analysis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Purpose Air pollution has been linked to several neurological conditions, including stroke and neurodegenerative diseases. Evidence regarding its association with multiple sclerosis (MS) remains conflicting, limited by small sample sizes. Methods PubMed, Embase, Scopus, and Cochrane controlled register of trials (CENTRAL) were searched on ...
Ahmad A. Toubasi, Thuraya N. Al‐Sayegh
wiley   +1 more source

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. [PDF]

, 2018
BackgroundNo evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used
Arnold, Douglas L, Bar-Or, Amit, Belachew, Shibeshih, Bennett, Iain, Buffels, Regine, Comi, Giancarlo, Garren, Hideki, Giovannoni, Gavin, Han, Jian, Hartung, Hans-Peter, Hauser, Stephen L, Havrdová, Eva, Julian, Laura, Kappos, Ludwig, Lublin, Fred, Napieralski, Julie, Selmaj, Krzysztof, Traboulsee, Anthony   +17 more
core   +1 more source

Structure–Function Decoupling of the Sensorimotor and Default Mode Networks in Black Americans With MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Objectives Multiple sclerosis (MS) exhibits racially disparate rates of disease progression. Black people with MS (B‐PwMS) experience a more severe disease course than non‐Hispanic White people with MS (NHW‐PwMS). Here we investigated structural and functional connectivity as well as structure–function decoupling in the ...
Emilio Cipriano, Giacomo Boffa, Maria Petracca, Marta Ponzano, Nicole Graziano, Claire Wigley, Claire Riley, Jonathan Howard, Pietro Bontempi, Sylvia Klineova, Fred Lublin, Matilde Inglese   +11 more
wiley   +1 more source